Temporal Trends and Predictors in the Use of Stereotactic Body Radiotherapy for Treatment of Metastatic Renal Cell Carcinoma in the U.S-Reference-Cited by-同舟云学术

Temporal Trends and Predictors in the Use of Stereotactic Body Radiotherapy for Treatment of Metastatic Renal Cell Carcinoma in the U.S

Published:2021-03-24 Issue:5 Volume:26 Page:e905-e906
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

Paciotti Marco¹²,Schmidt Andrew L.³,Ravi Praful³,McKay Rana R.⁴,Trinh Quoc-Dien¹,Choueiri Toni K.³

Affiliation:

1. Division of Urological Surgery and Center for Surgery and Public Health, Brigham and Women's Hospital, Boston, Massachusetts, USA

2. Department of Urology, Humanitas Clinical and Research Center IRCCS, Rozzano, Italy

3. Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

4. Department of Medicine, Division of Hematology/Oncology, University of California San Diego, San Diego, California, USA

Abstract

This letter to the editor outlines the use of stereotactic body radiotherapy for metastatic renal cell carcinoma in the U.S., identifying clinical predictors of utilization using the National Cancer Database.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/onco.13736

Reference7 articles.

1. Outcomes of stereotactic radiotherapy for cranial and extracranial metastatic renal cell carcinoma: A systematic review;Kothari;Acta Oncol,2015

2. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): A randomised, phase 2, open-label trial;Palma;Lancet,2019

3. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma;Méjean;N Engl J Med,2018

4. Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: The SURTIME randomized clinical trial;Bex;JAMA Oncol,2019

5. Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK);Lalani;J Clin Oncol,2020

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Active Surveillance in Metastatic Renal Cell Carcinoma;Journal of Kidney Cancer and VHL;2024-06-04

2. Incorporating Stereotactic Ablative Radiotherapy into the Multidisciplinary Management of Renal Cell Carcinoma;Current Oncology;2023-12-01

3. The Role of Stereotactic Ablative Body Radiotherapy in Renal Cell Carcinoma;European Urology;2022-12

4. A Nanomedicine Structure–Activity Framework for Research, Development, and Regulation of Future Cancer Therapies;ACS Nano;2022-11-02

5. Longitudinal Molecular Profiling of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma;Journal of Clinical Oncology;2022-11-01